Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience.

Munteanu M; Ratziu V; Morra R; Messous D; Imbert-Bismut F; Poynard T

Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience.

Munteanu M, Ratziu V, Morra R, Messous D, Imbert-Bismut F …

MeSH — NLM indexing Biomarkers / blood Diagnosis, Differential Fatty Liver / blood Fatty Liver / complications Fatty Liver / diagnosis Hepatitis / blood Hepatitis / complications Hepatitis / diagnosis Humans Liver Cirrhosis / blood Liver Cirrhosis / complications Liver Cirrhosis / diagnosis Mass Screening / methods Metabolic Syndrome / blood Metabolic Syndrome / complications Risk Factors

Staff actions

Download PDF

Files are for authorised use within BioPredictive partner channels only.

Key publication Nash Fibrotest Review Our Group France

Authors (6)

Munteanu M — Biopredictive, and Groupe Hospitalier Pitié Salpêtrière, 47-83 Boulevard de l'Hopital, Paris, France. mona.munteanu@biopredictive.com
Ratziu V
Morra R
Messous D
Imbert-Bismut F

Munteanu M — Biopredictive, and Groupe Hospitalier Pitié Salpêtrière, 47-83 Boulevard de l'Hopital, Paris, France. mona.munteanu@biopredictive.com
Ratziu V
Morra R
Messous D
Imbert-Bismut F
Poynard T

Citation

Munteanu M, Ratziu V, Morra R, Messous D, Imbert-Bismut F, Poynard T. Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience. J Gastrointestin Liver Dis. 2008;17(2):187-91. PMID:18568141.

Identifiers

PMID: 18568141

Tests

Liver diseases

Liver injuries

Subjects

Risk factors

Region

Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience.

More by Munteanu M

Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease.

Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference.

Biopsy as well as FibroTest/Fibrosure is suboptimal for discriminating intermediate fibrosis stages in patients with chronic hepatitis B.

FibroTest (FT) has similar accuracy for cirrhosis in 'intention-to-diagnose' which is superior to transient elastography (TE) in chronic hepatitis B.

Letter: FibroTest for staging fibrosis in non-alcoholic fatty liver disease.

FibroStic: a large confirmatory study for non-invasive biomarkers accuracy, if correctly interpreted.

More on the same topic

An Invisible Early Steatosis Phenotype Defined for a Large Population-Based Cohort.

Diagnostic performance of FibroTest-ActiTest, transient elastography, and the fibrosis-4 index in patients with autoimmune hepatitis using histological reference.

Metabolic dysfunction-associated steatotic liver disease (MASLD) biomarkers and progression of lower limb arterial calcification in patients with type 2 diabetes: a prospective cohort study.

Noninvasive Assessment of Liver Fibrosis.

Screening for Metabolic Dysfunction-Associated Steatotic Liver Disease-Related Advanced Fibrosis in Diabetology: A Prospective Multicenter Study.

Three Neglected STARD Criteria Reduce the Uncertainty of the Liver Fibrosis Biomarker FibroTest-T2D in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).